Next week at ASCO24 💡“𝗕𝗿𝗲𝗔𝗞 𝗖𝗥𝗖, 𝗮 𝗳𝗶𝗿𝘀𝘁-𝗶𝗻-𝗵𝘂𝗺𝗮𝗻 𝗽𝗵𝗮𝘀𝗲 𝗜/𝗜𝗜 𝘁𝗿𝗶𝗮𝗹 𝗼𝗳 𝗦𝗧𝗖-𝟭𝟬𝟭𝟬, 𝗮 𝗻𝗲𝘄 𝗮𝗹𝗹𝗼𝗴𝗲𝗻𝗶𝗰 𝗰𝗮𝗻𝗰𝗲𝗿 𝘃𝗮𝗰𝗰𝗶𝗻𝗲 𝗳𝗼𝗿 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗼𝗿 𝗺𝗲𝘁𝗮𝘀𝘁𝗮𝘁𝗶𝗰 𝘂𝗻𝗿𝗲𝘀𝗲𝗰𝘁𝗮𝗯𝗹𝗲 𝗰𝗼𝗹𝗼𝗿𝗲𝗰𝘁𝗮𝗹 𝗰𝗮𝗻𝗰𝗲𝗿.”
Brenus Pharma is excited to present a new poster accepted at American Society of Clinical Oncology (ASCO) annual meeting in Chicago during the “Trials in Progress” session. ⬇️
Contact & meet Corinne TORTORELLI, Poster hashtag295b
🗓️ 6/1/2024, 1:30 PM-4:30 PM CDT
📣”𝘉𝘳𝘦𝘈𝘒-𝘊𝘙𝘊 𝘪𝘴 𝘮𝘦𝘢𝘯𝘵 𝘵𝘰 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭𝘭𝘺 𝘤𝘰𝘯𝘧𝘪𝘳𝘮 𝘵𝘩𝘦 𝘱𝘳𝘰𝘮𝘪𝘴𝘪𝘯𝘨 𝘱𝘳𝘦𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘰𝘶𝘵𝘤𝘰𝘮𝘦𝘴 𝘰𝘣𝘵𝘢𝘪𝘯𝘦𝘥 𝘰𝘯 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘵 𝘴𝘺𝘯𝘨𝘦𝘯𝘦𝘪𝘤 𝘮𝘰𝘶𝘴𝘦 𝘮𝘰𝘥𝘦𝘭𝘴 𝘢𝘯𝘥 𝘦𝘹-𝘷𝘪𝘷𝘰 𝘢𝘴𝘴𝘢𝘺𝘴 𝘢𝘣𝘰𝘶𝘵 𝘵𝘩𝘦 𝘱𝘰𝘵𝘦𝘯𝘵𝘪𝘢𝘭 𝘮𝘢𝘫𝘰𝘳 𝘵𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘪𝘮𝘱𝘢𝘤𝘵 𝘰𝘧 𝘚𝘛𝘊-1010 𝘰𝘯 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘪𝘵𝘩 𝘱𝘔𝘔𝘙/𝘔𝘚𝘚 𝘢𝘯𝘥 𝘥𝘔𝘔𝘙/𝘔𝘚𝘐-𝘏 𝘐𝘊𝘐-𝘳𝘦𝘴𝘪𝘴𝘵𝘢𝘯𝘵 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘥 𝘰𝘳 𝘮𝘦𝘵𝘢𝘴𝘵𝘢𝘵𝘪𝘤 𝘶𝘯𝘳𝘦𝘴𝘦𝘤𝘵𝘢𝘣𝘭𝘦 𝘤𝘰𝘭𝘰𝘳𝘦𝘤𝘵𝘢𝘭 𝘤𝘢𝘯𝘤𝘦𝘳𝘴”
Stay tuned !!
Biotech hashtagImmunotherapy hashtagCancervaccine hashtagColorectalcancer hashtagClinicalstudy hashtagOncology
